Earlier quoted context omitted.
To be clear - during 2014-2019 NIH actually paid $3.6M to EcoHealth Alliance under the grants clearly specifying the coronavirus GoF experiments in Wuhan with the "Human subjects included" checked. EcoHealth naturally kept about 75% of it as "commission/management fee/whatever" because conducting those experiments at BSL2 in Wuhan was much cheaper than the original experiments in US at BSL3+ (in those original experi…
> during 2014-2019 NIH actually paid $3.6M to EcoHealth Alliance under the grants clearly specifying the coronavirus GoF experiments in Wuhan with the "Human subjects included" checked. Is this is the grant you're referring to? https://reporter.nih.gov/search/me9X23pZWEigATS-4XTBfA/proje... From your comment it was unclear to me what the human subjects component was. It appears to have been population surveillance us…
https://www.technologyreview.com/2021/06/29/1027290/gain-of-...
" Baric had developed a way around that problem—a technique for “reverse genetics” in coronaviruses. Not only did it allow him to bring an actual virus to life from its genetic code, but he could mix and match parts of multiple viruses. He wanted to take the “spike” gene from SHC014 and move it into a genetic copy of the SARS virus he already had in his lab. The spike molecule is what lets a coronavirus open a cell and get inside it. The resulting chimera would demonstrate whether the spike of SHC014 would attach to human cells.
...
In 2014, the NIH awarded a five-year, $3.75 million grant to EcoHealth Alliance to study the risk that more bat-borne coronaviruses would emerge in China, using the same kind of techniques Baric had pioneered. Some of that work was to be subcontracted to the Wuhan Institute of Virology.
...
In 2017, Daszak and Shi followed with another study, also at BSL-2, that one-upped Baric’s work in North Carolina. The WIV had continued to unearth dozens of new SARS-like coronaviruses in bat caves, and it reported making chimeras with eight of them by fusing the spikes of the new viruses to the chassis of WIV1. Two of them replicated well in human cells. They were, for all intents and purposes, brand-new pathogens.
"